ClinicalTrials.gg
Active, not recruitingNCT05266924REFRESHUpdated Aug 1, 2023

Recombinant Follicle-stimulating Hormone in Treatment for Infertility

A Phase 3 interventional study of Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen in Female Infertility, sponsored by Bharat Serums and Vaccines Limited. Active, not recruiting at 1 site in India. Open to female participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Bharat Serums and Vaccines Limited · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2023, 3 years 2 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
20 Years to 39 Years
Sex
Female
01

Study summary

This is a randomized multi-centre, assessor-blind, parallel-group study to be conducted in 250 women in the age group of 20 to 39 years (both inclusive), who are indicated to undergo COS as part of assisted reproductive technology (ART). The participant will receive r-hFSH, fixed-dose for 5 days, and day 6 onwards the dose may be adjusted for a single cycle of COS followed by ART procedures, and post-ART follow-up for ongoing pregnancy.

The primary and secondary outcomes will be captured on days as per protocol. Adverse events will be noted for safety evaluation.

02

Conditions studied

  • Female Infertility

Browse trials for

03

In context

Infertility, Female

552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.

This study's planned enrollment of 250 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.

Browse Infertility, Female studies →

Lead sponsor

Bharat Serums and Vaccines Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subject has indication ART using COS.
  • Subject has regular menstrual cycle of 21-35 days.
  • Subject has one of the following:

    1. FSH level \<10 IU/L and Estradiol levl \<80 pg/mL at day 2 or 3
    2. Anti-mullerian hormone (AMH) level between 1 to 3.5 ng/mL during the menstrual cycle
  • Subject has an antral follicle count (AFC) of 10- 25, follicle ≤10 mm in diameter before ovarian stimulation
  • Subject has a ≥18 and \<30 kg/m2
  • Subject has results of clinical laboratory tests within normal reference range
  • Subject and her partner are willing to provide written and comply

Exclusion Criteria Details Subject has history of >2 failed ART cycles

  • Subject with history of any endocrine abnormality, with documented hormone levels outside the reference range, which are , at screening
  • Subject with a history of ovarian hyper-response (i.e., previous COS cycle with >25 follicles of ≥11 mm in diameter on USG) or OHSS
  • Subject with documented polycystic ovarian syndrome (PCOS) at the time of screening
  • Subject with only one ovary or ovarian abnormality (including endometrioma >10 mm; visible on USG), at screening
  • Subject with documented severe endometriosis (American Society of Reproductive Medicine stage 3 or stage 4) or hydrosalpinx, at screening
  • Subject with submucosal fibroids ≥5 cm or any other clinically relevant pathology, which could impair embryo implantation or pregnancy continuation, at screening
  • Subject with a history of extrauterine pregnancy within 3 months of screening
  • Subject with history of poor response to gonadotropin treatment (retrieval of \<4 oocytes) in the previous ART cycle
  • Subject with history of ≥3 miscarriages, at any time prior to screening
  • Subject who has tested positive for , or at screening
  • Subject known to be allergic, hypersensitive, or intolerant to any of the preparations of r hFSH or its , that will be used in the study
  • Subject with to the use of gonadotropins (e.g., tumours, undiagnosed vaginal bleeding, or ovarian cysts) or gonadotropin-releasing hormone (GnRH) antagonists
  • Subject with a history of epilepsy, thrombophilia, cardiovascular, gastrointestinal, hepatic, renal, pulmonary, auto-immune disease, or any active infection, requiring treatment which at the investigator's discretion might interfere with the study
  • Subject with history of
  • Subject who smokes or has stopped smoking within the last 3 months prior to screening
  • Subject with history of alcohol or drug abuse within 12 months prior to screening
  • Subject who has received any treatment listed below within 5 half-lives prior to screening:

    1. Any agent(s) known to affect ovulation (e.g., neuroleptics);
    2. Drugs known or suspected to be teratogenic in nature.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Test group

    Foligraf 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen Follicle Stimulating Hormone (Human Recombinant) manufactured by Bharat Serums and Vaccines Ltd

    Drug: Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen

  • Active comparator
    Reference group

    Gonal-f Recombinant Human Follicle Stimulating Hormone

    Drug: Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen

Interventions

  • DrugRecombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen

    Drug page: Follitropin alfa

    fixed-dose of 225 IU/day, subcutaneous (SC), daily, for 5 days. further dosage will be adjusted till adequate follicular development.

    Also known as: Foligraf, Gonal-f

06

What researchers measure

Primary outcomes

  1. Number of oocytes retrieved

    Number of oocytes retrieved

    Time frame: Oocyte pick up - up to ~ 34 to 36 hours after human chorionic gonadotropin (hCG) administration

Secondary outcomes

  1. Clinical pregnancy rate

    Clinical pregnancy rate

    Time frame: 4 weeks after embryo transfer (ET)

  2. Ongoing Pregnancy rate

    Ongoing pregnancy rate

    Time frame: 11±1 weeks after ET

  3. Cycle cancellation rate

    Cycle cancellation rate

    Time frame: at Stimulation phase up to 20 days, oocyte pick up up to ~ 34 to 36 hours after hCG administration, ET anytime up to 8 weeks

  4. Total Doseof r-hFSH

    Total dose of r-hFSH (in IU) required for ovarian stimulation;

    Time frame: at end of stimulation up to 20 days

  5. Number of Days of r-hFSH stimulation

    Number of days of r-hFSH stimulation

    Time frame: at end of stimulation up to 20 days

  6. Number of subject Change in Dosage

    Proportion of subjects requiring change in dose

    Time frame: post Day 6 till end of stimulation up to 20 days

  7. Hormonal Investigation

    Estradiol, Luteinizing, Progesterone, and inhibin b levels

    Time frame: Day 6

  8. Follicle size on Day 6

    Number of follicles with size \<11mm, Number of follicles with size 11- 14 mm, Number of follicles with size15 mm, Number of follicles with size16 mm, Number of follicles with size17 mm and Number of follicles with size ≥18 mm

    Time frame: Day 6

  9. Follicle size at HCG administration

    Number of follicles with size \<11mm, Number of follicles with size 11- 14 mm, Number of follicles with size15 mm, Number of follicles with size16 mm, Number of follicles with size17 mm and Number of follicles with size ≥18 mm mm)

    Time frame: Day of hCG administration anytime upto 3 weeks

  10. Endometrium thickness

    Endometrial thickness (mm)

    Time frame: day 6

  11. Endometrium at HCG administration

    Endometrial thickness (mm)

    Time frame: day of hCG injection (anytime upto 3 weeks)

  12. Number of Matured oocytes

    Proportion of matured oocytes

    Time frame: Oocyte pick up ~ 34 to 36 hours after hCG administration

  13. Number of good quality embryos

    Number of good quality embryos

    Time frame: ET day (up to 8 weeks)

  14. Number of Adverse events

    Number of treatment-emergent adverse events (TEAE) reported

    Time frame: Baseline, 1st day of stimulation, day 6 , end of stimulation up to 20 days, hCG administration, oocyte pick up ~ 34 to 36 hours after hCG administration, ET up to 8 weeks, clinical pregnancy (after 4 weeks of ET), ~12 weeks after ET

  15. Specific adverse events

    The number of patients with ovarian hyperstimulation syndrome (OHSS) reported

    Time frame: Day 1 of Stimulation till ~12 weeks after ET

  16. Exploratory

    Ease of use of Pen - comparison of total score of Questionnaire to user of rhFSH pen

    Time frame: End of stimulation up to 20 days

  17. Evaluation of immunogenicity (antibody) of r-hFSH

    Evaluation of immunogenicity of r-hFSH, comparison of antibody titre against r-hFSH in both groups

    Time frame: Baseline, 4 weeks and 12 weeks

07

Study locations

1 site
  • Om Research Center Om Surgical Center and Maternity Home
    Varanasi, Uttar Pradesh 221007, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Aug 2023, 13 months after the start.

Of 28 phase 3 interventional studies under Infertility, Female, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2022
First posted
Mar 4, 2022
StartActual
Jul 23, 2022
Primary completionEst.
Aug 31, 2023
CompletionEst.
Nov 30, 2023
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05266924
Lead sponsor
Bharat Serums and Vaccines Limited
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
Jul 23, 2022
Primary completion
Aug 31, 2023 (estimated)
Completion
Nov 30, 2023 (estimated)
Last update
Aug 1, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion